Hepatitis A Vaccine

Virosomal hepatitis A vaccine (Epaxal) protects against infection

Published in Medical Letter on the CDC and FDA, February 1st, 2004

A virosomal hepatitis A vaccine (Epaxal) protected against infection in young children.

According to a study from Lithuania, "To evaluate the immunogenicity and tolerability of Epaxal in infants and children, 30 infants (aged six to seven months) and 30 children (aged five to seven years) received a single intramuscular dose of the aluminum-free virosomal hepatitis A virus (HAV) vaccine Epaxal and a booster dose after 12 months. Anti-HAV antibody titers were measured at baseline (before injection), at 1 and 12 months after primary vaccination, and one month after the booster vaccination."

"Sixteen evaluable infants had maternal anti-HAV antibodies at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-02-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry